文献速递淋巴瘤

成人T细胞白血病中TP73及其内含子超级增强子来源遗传改变的必要性

Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.
PubMed 文献 · Leukemia · 2022-07-30

研究探讨TP73及其超级增强子在成人T细胞白血病/淋巴瘤(ATL)中的作用。TP73在ATL细胞中受超级增强子调控高表达,全长TP73对ATL细胞体外和体内维持至关重要。部分原发ATL病例存在TP73外显子2-3复发性缺失,诱导该缺失可增加细胞增殖和突变负荷。

要点

  • TP73在ATL细胞中受超级增强子调控高表达,正常T细胞及其他血液肿瘤中未观察到。
  • 全长TP73通过调控细胞增殖和DNA损伤应答通路维持ATL细胞体外和体内存活。
  • 部分携带超级增强子的原发ATL病例存在TP73外显子2-3复发性缺失,诱导该缺失增加增殖和突变负荷。

核心结论

  • TP73内含子超级增强子的形成和遗传缺失可能在ATL细胞胞内状态相关下序贯获得,导致TP73功能改变并赋予额外克隆优势。

研究设计与样本

  • 研究采用整合性方法,基于既往鉴定的ATL中反复与超级增强子相关的基因,对TP73及其超级增强子在ATL发病中的作用和功能进行实验研究。

主要发现

  • TP73在ATL细胞中受超级增强子控制高度激活,而在正常T细胞或所检查的其他血液恶性肿瘤中未观察到。
  • 全长TP73通过调控细胞增殖和DNA损伤应答通路,为ATL细胞体外和体内维持所必需。
  • 部分携带超级增强子的原发ATL病例中观察到TP73外显子2-3的复发性缺失。
  • 在细胞系中诱导该缺失进一步增加增殖和突变负荷。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adult T-cell leukemia/lymphoma (ATL) is a genetically complex hematological malignancy derived from mature T cells. Using an integrative approach, we previously identified genes recurrently associated with super-enhancers in ATL. One of those genes was TP73, a TP53 family gene; however, the roles and function of TP73 and its super-enhancer in ATL pathogenesis are poorly understood. Our study demonstrates that TP73 is highly activated under the control of a super-enhancer in ATL cells but not in normal T cells or other hematological malignancies examined. Full-length TP73 is required for ATL cell maintenance in vitro and in vivo via the regulation of cell proliferation and DNA damage response pathways. Notably, recurrent deletions of TP73 exons 2-3 were observed in a fraction of primary ATL cases that harbored the super-enhancer, while induction of this deletion in cell lines further increased proliferation and mutational burden. Our study suggests that formation of the TP73 intragenic super-enhancer and genetic deletion are likely sequentially acquired in relation to intracellular state of ATL cells, which leads to functional alteration of TP73 that confers additional clonal advantage.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ong JZL, Yokomori R, Wong RWJ, et al. Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia. Leukemia. 2022. PMID: 35908104. doi:10.1038/s41375-022-01655-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。